The treatment of Parkinson's disease in older people.
Parkinson's disease is characterised by a variable combination of tremor, rigidity, bradykinesia and impaired righting reflexes. The cumulative life-time risk is one in 40. Levodopa remains the single most effective treatment in older patients, and the minimum dose to achieve maximum functional benefit should be employed. When fluctuations occur, controlled release preparations and selegiline can improve function. Oral dopamine agonists have a role but the combined side effect profile with levodopa should be monitored. COMT inhibitors have recently become available. Subcutaneous apomorphine can be helpful when "on-off" phenomena are marked. The concept of neuroprotection continues to be debated. Surgery is an option for fitter older people but neurotransplantation remains essentially a research tool.
Lien
C T
CT
Department of Medicine for the Elderly, Dundee Healthcare NHS Trust, Royal Victoria Hospital.
Mutch
W J
WJ
D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D065098:Catechol O-Methyltransferase Inhibitors; D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010300:Parkinson Disease / Q000628:therapy*; D012307:Risk Factors; D013238:Stereotaxic Techniques; D013788:Thalamus / Q000601:surgery
D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D018491:Dopamine Agonists; D018696:Neuroprotective Agents